*Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.
^†ISTH major bleed assessed by a sequential testing strategy for superiority designed to control the overall type I error in the trial. Major bleeding was defined as clinically overt bleeding that was accompanied by 1 or more of the following: A decrease in hemoglobin of 2 g/dL or more; a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; or bleeding that was fatal. Intracranial hemorrhage included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds.
^‡GI bleed includes upper GI, lower GI, and rectal bleeding.
^§Intraocular bleed is within the corpus of the eye (a conjunctival bleed is not an intraocular bleed).
^||Fatal bleed is an adjudicated death due to bleeding during the treatment period and includes both fatal extracranial bleeds and fatal hemorrhagic stroke.

CI, confidence interval; CRNM, clinically relevant nonmajor bleeding; GI, gastrointestinal; HR, hazard ratio; ISTH, International Society on Thrombosis and Haemostasis.